申请人:——
公开号:US20040082596A1
公开(公告)日:2004-04-29
The invention relates to novel pyrazolopyridine derivatives of the formula (I), wherein R1 represents hydrogen or a di-C1-6-alkylaminocarbonyl group, R2 represents a rest of the formula —O—CO—NR3R4, wherein R3 and R4 are the same or different and represent a rest of the group comprising optionally substituted C
1-6 alkyl, optionally substituted C
2-6 ?alkenyl, or optionally substituted C
3-8 ? cycloalkyl: or which, together with the nitrogen atom to which they are bound, form a five- to seven-membered saturated heterocycle that may optionally contain an additional hetero atom from the group N, O, S and/or that may be optionally substituted, and to the salts, isomers and hydrates of said derivatives, as stimulants of the soluble guanylate cyclase and for use as agents for treating cardiovascular diseases, hypertonia, thromboembolic diseases and ischemia, sexual dysfunction or inflammations, and for treating diseases of the central nervous system.
本发明涉及式(I)的新型吡唑吡啶衍生物,其中R1代表氢或二C1-6-烷基氨甲酰基基团,R2代表公式中的其余部分—O—CO—NR3R4,其中R3和R4相同或不同,代表包括可选取代的C1-6烷基、可选取代的C2-6烯基或可选取代的C3-8环烷基的基团,或者它们与它们所连接的氮原子一起形成五元至七元的饱和杂环,该杂环可以选择性地包含来自N、O、S等杂原子组成的附加杂原子,或者可以选择性地取代。本发明还涉及所述衍生物的盐、异构体和水合物,作为可溶性鸟苷酸环化酶的刺激剂,并用作治疗心血管疾病、高血压、血栓栓塞性疾病和缺血、性功能障碍或炎症以及治疗中枢神经系统疾病的药物。